Prostate Cancer Section Head News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ASCO 2024: A Phase 1 Study of JNJ-69086420 (JNJ-6420), an Actinium-225 (225Ac)-Labeled Antibody Targeting Human Kallikrein 2, for mCRPC

ASCO 2024, prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), JNJ-69086420 (JNJ-6420), Actinium-225 (225Ac), Targeting Human Kallikrein 2, JNJ-6420 adverse events.

Memorial sloan kettering cancer centerNew yorkUnited statesMichaelj morrisMichael morrisZachary klaassenAmerican society of clinical oncologyGeorgia cancer centerClinical oncologyProstate cancer section headUrologic oncologistAssociate professorAnnual meeting

APCCC 2024: Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice?

APCCC 2024: Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice?
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMemorial sloan kettering cancer centerMichael morrisSociety of urologic oncologyProstate cancer working groupUniversity of torontoInternational multicenter studyDivision of solid tumor oncologyProstate cancer consensus conferenceResponse evaluation usingMetastatic castration resistant prostate cancerMedical oncologistClinical directorGenitourinary medical oncology serviceProstate cancer section head

ESMO 2021: PSMAfore: A Phase 3 Study To Compare 177Lu-PSMA-617 Treatment With a Change in Androgen Receptor Pathway Inhibitor in Taxane-Naïve Patients With mCRPC

ESMO 2021: PSMAfore: A Phase 3 Study To Compare 177Lu-PSMA-617 Treatment With a Change in Androgen Receptor Pathway Inhibitor in Taxane-Naïve Patients With mCRPC
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMemorial sloan kettering cancer centerMichael morrisChristopher jd wallisUniversity of torontoEuropean society for medical oncologyEuropean societyMedical oncologyAnnual congressProstate cancer section headபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்நினைவகம் ஸ்லோன் கெட்டரிங் புற்றுநோய் மையம்மைக்கேல் மோரிஸ்கிறிஸ்டோபர் ஜ்ட் வாலிஸ்

ASCO 2021: Phase III Study of Lutetium-177-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)

ASCO 2021: Phase III Study of Lutetium-177-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

Memorial sloan kettering cancer centerNew yorkUnited statesMichael morrisChristopher jd wallisVanderbilt university medical centerAmerican society of clinical oncologyDivision of solid tumor oncologyClinical oncologyAnnual meetingMedical oncologist clinical directorGenitourinary medical oncology serviceProstate cancer section headSolid tumor oncologyUrologic oncology fellowVirtual annual meeting